Latanoprost Genoptim

Latanoprost, the active ingredient in Genoptim, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Genoptim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used in the management of ocular conditions that require reduction of intra‑ocular pressure.

Open‑angle glaucoma: lowers eye pressure to slow disease progression. Ocular hypertension: reduces intra‑ocular pressure to prevent development of glaucoma. Elevated intra‑ocular pressure: helps maintain target pressure in patients at risk of optic nerve damage.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual pigmentation change. - Eye irritation: transient burning or stinging. - Blurred vision: temporary focus disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Vision loss: sudden decrease in visual acuity. - Ocular infection: signs of bacterial or fungal involvement.

Before using Latanoprost, consider the following safety measures.

Monitor intra‑ocular pressure: ensure target pressure is achieved. Assess for ocular inflammation: avoid use during active uveitis. Avoid contact lenses: remove lenses before instillation. Inform ophthalmologist of other eye medications: prevent additive effects. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: may increase ocular side effects. - Systemic carbonic anhydrase inhibitors: additive IOP‑lowering may cause hypotony. - Ocular corticosteroids: may reduce Latanoprost efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may increase irritation. - Beta‑blocker eye drops: monitor for excessive IOP reduction. - Systemic antihistamines: may affect tear production and comfort.